Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | IDH1 | O75874 | 5/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075164 | 1.00 | RAB9A (0.50) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4077340 | 1.00 | RAB9A (0.50) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4080528 | 0.86 | ALDH1A1 (0.46) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4075686 | 0.85 | CA1 (0.47) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4492132 | 0.85 | GAA (0.54) | MEN1KMT2AMAPTIDH1 | |
| SCHEMBL4075212 | 0.85 | CA1 (0.47) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4075521 | 0.85 | GAA (0.54) | MEN1KMT2AMAPTIDH1 | |
| SCHEMBL4074059 | 0.85 | GAA (0.54) | MEN1KMT2AMAPTIDH1 | |
| SCHEMBL4076669 | 0.85 | CA1 (0.47) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4077649 | 0.85 | IDH1 (0.52) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | claimed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | claimed |
| US-7652018-B2 | Imidazolidin-2-one derivatives useful as PR modulators | WYETH LLC (US) | 2010-01-26 | — | — | US | disclosed |
| US-7649007-B2 | Oxazolidine derivatives as PR modulators | WYETH LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7618989-B2 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| US-7618990-B2 | 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy | WYETH (US) | 2009-11-17 | — | — | US | disclosed |
| CN-101501031-A | Oxazolidone derivatives as pr modulators | WYETH CORP (US) | 2009-08-05 | — | — | CN | disclosed |
| US-7538107-B2 | Oxazinan-2-one derivatives useful as PR modulators | WYETH (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045579-A1 | Oxazolidine derivatives as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
| US-20080045518-A1 | Oxazinan-2-one derivatives useful as PR modulators | WYETH (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045518-A1 | Oxazinan-2-one derivatives useful as PR modulators | NPY1R, OXTR, GNRHR | RAB9A 2511/4885SMN1; SMN2 2791/4885MEN1 177/4885 |
| US-20080045577-A1 | 4-[2-(3,5,5-Trimethyl-2-oxoimidazolidin-1-yl)-1,3-thiazol-4-yl]benzonitrile; 1-[4-(4-Bromophenyl)-1,3-thiazol-2-yl]-3-methylimidazolidin-2-one; contraception, fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas | PKD1, SHBG, NPY4R | RAB9A 2193/4885SMN1; SMN2 3676/4885MEN1 30/4885 |
| US-20080045560-A1 | Pyrrolidine and related derivatives useful as PR modulators | PRLHR, GNRHR, NPY1R | RAB9A 830/4885SMN1; SMN2 3154/4885MEN1 135/4885 |
| US-20080045578-A1 | Tricyclic oxazolidone derivatives useful as PR modulators | MC2R, GNRHR, MC3R | RAB9A 2089/4885SMN1; SMN2 3186/4885MEN1 656/4885 |
| US-20080045579-A1 | Oxazolidine derivatives as PR modulators | NPY1R, GNRHR, KISS1R | RAB9A 469/4885SMN1; SMN2 3158/4885MEN1 142/4885 |
| US-20080045556-A1 | Oxazolidone derivatives as PR modulators | MC2R, NPY1R, PRLHR | RAB9A 1677/4885SMN1; SMN2 3382/4885MEN1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.